Changing the course of pain and inflammatory disease
Who we are
Adynxx is a clinical stage biopharmaceutical company focused on bringing to market novel, disease-modifying products for the treatment of pain and inflammation. Since its founding in 2007, Adynxx has worked to discover and develop transcription factor decoys to modify the course of pain, to collaborate with discovery partners, and to identify in-licensing opportunities with transformative therapeutic profiles to build a pipeline in pain and inflammation.
Discover and develop novel, disease-modifying products for pain and inflammation
Developing transformative, first-in-class therapies to address significant unmet medical needs
A proprietary platform of non-opioid, disease-modifying oligonucleotide therapeutics
Tackling high unmet need
Focusing on patients who have the greatest need for innovative pain treatments
News & Publications
Dec 13, 2018
SAN FRANCISCO, Calif., December 13, 2018 -- Adynxx, Inc., a clinical-stage biotechnology company focused on developing transformative therapies for pain and inflammatory diseases, today announced receipt of Notice of Award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), for an award to support the clinical development of the company’s lead product candidate, brivoligide injection (brivoligide) for postoperative pain.
Meet our team
Experienced management team with a proven track record of success dedicated to improving the life of patients